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In the initial weeks of HIV infection of humans 
and pathogenic simian immunodeficiency virus 
(SIV) infection of Asian macaques, viral repli-
cation peaks, then declines to a quasiequili-
brated set point of ongoing viral production 
and clearance, the level of which plays a major 
role in determining the subsequent tempo of 
disease progression (Mellors et al., 1996; Staprans 
et al., 1999). Outcomes range from an inability 
to substantially restrain viral replication from 
peak levels, leading to early immunological 
collapse and rapid progression to AIDS, to con-
trol of viral replication to undetectable levels 
and long-term nonprogression (Farzadegan et al., 
1996; Picker et al., 2004; Deeks and Walker, 
2007; Goulder and Watkins, 2008). However, 
the vast majority of infections manifest viral repli-
cation set points and progression rates between 
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Depletion of CD8+ lymphocytes during acute simian immunodeficiency virus (SIV) infection 
of rhesus macaques (RMs) results in irreversible prolongation of peak-level viral replication 
and rapid disease progression, consistent with a major role for CD8+ lymphocytes in deter-
mining postacute-phase viral replication set points. However, we report that CD8+ lympho-
cyte depletion is also associated with a dramatic induction of proliferation among CD4+ 
effector memory T (TEM) cells and, to a lesser extent, transitional memory T (TTrM) cells, 
raising the question of whether an increased availability of optimal (activated/proliferat-
ing), CD4+/CCR5+ SIV “target” cells contributes to this accelerated pathogenesis. In keeping 
with this, depletion of CD8+ lymphocytes in SIV RMs led to a sustained increase in the 
number of potential CD4+ SIV targets, whereas such depletion in acute SIV infection led to 
increased target cell consumption. However, we found that the excess CD4+ TEM cell prolif-
eration of CD8+ lymphocyte–depleted, acutely SIV-infected RMs was completely inhibited 
by interleukin (IL)-15 neutralization, and that this inhibition did not abrogate the rapidly 
progressive infection in these RMs. Moreover, although administration of IL-15 during 
acute infection induced robust CD4+ TEM and TTrM cell proliferation, it did not recapitulate 
the viral dynamics of CD8+ lymphocyte depletion. These data suggest that CD8+ lymphocyte 
function has a larger impact on the outcome of acute SIV infection than the number and/
or activation status of target cells available for infection and viral production.
© 2009 Okoye et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.jem.org/misc/terms.shtml). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/
licenses/by-nc-sa/3.0/).
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the potential impact of vaccines and other immunomodulators 
on HIV/SIV pathogenesis. However, experimental dissection 
of these processes in vivo is complicated by the fact that primary 
viral targets—CD4+ memory T cells—are an intrinsic and   
essential part of the adaptive immune response and are almost 
invariably coregulated with CD8+ lymphocyte–mediated ef-
fector responses. In this paper, we report on the use of CD8+ 
lymphocyte depletion in RMs, which effectively eliminates 
CD8+ effector lymphocyte responses in acute SIV infection 
(Matano et al., 1998; Schmitz et al., 1999; Kim et al., 2008; 
Veazey et al., 2008), to determine the importance of target 
cell expansion and activation on viral dynamics in acute SIV 
infection. We document that CD8+ lymphocyte depletion 
induces massive selective proliferation of CD4+, CCR5+ 
memory T cell targets, leading to profound expansion of this 
population in uninfected RMs and their increased consump-
tion in acute SIV infection. Furthermore, we identify IL-15 
as the major mediator of this proliferative response. Signifi-
cantly, however, in vivo inhibition of IL-15 by administration 
of a neutralizing anti–IL-15 mAb during CD8+ lymphocyte 
depletion of acutely SIV-infected RMs blocked induction of 
CD4+ target cell proliferation, but did not reverse either the 
high viral replication or rapid disease progression in CD8+ 
lymphocyte–depleted, acutely infected animals. Moreover, 
administration of exogenous IL-15 during acute SIV infec-
tion in RMs with an intact CD8+ lymphocyte compartment 
stimulated CD4+ target cell proliferation with kinetics similar 
to CD8+ lymphocyte depletion, but did not recapitulate the 
early viral dynamics of CD8+ lymphocyte depletion. Collec-
tively, these data provide compelling evidence that the rela-
tive effectiveness of adaptive and/or innate immune function 
of CD8+ lymphocytes plays a considerably more significant 
role in determining outcome of acute SIV infection than dif-
ferences in target cell number and/or activation status.
RESULTS
CD8+ lymphocyte depletion during acute SIVmac239 
infection abrogates the postpeak decline in viral replication 
and results in rapid disease progression
i.v. administration of highly pathogenic, CCR5-tropic SIV 
(SIVmac239 or SIVmac251) to Indian-origin RMs results 
in a characteristic pattern of plasma viremia arising from the 
massive, systemic infection of CD4+ memory T cells (Picker 
et al., 2004; Mattapallil et al., 2005; Grossman and Picker, 
2008). As shown in Fig. 1, acute-phase plasma viral loads peak 
at postinfection day (PID) 10 at a mean value of 3 × 107 SIV 
RNA copy equivalents/ml, and in typical infections, those 
destined for AIDS-free survival for >200 d (“normal” pro-
gressors; Picker et al., 2004), plasma viral loads drop by a mean 
of 1.85 logs in the subsequent 32 d to a stable plateau-phase 
level. In RMs administered the depleting, CD8-specific 
mAb cM-T807 concomitant with SIV infection, mean plasma 
viral loads are identical to control infections through PID 10, but 
in these CD8+ lymphocyte–depleted RMs (see also Fig. 5 A), 
plasma viral loads continue to rise from PID 10 to 14 by a mean 
of 0.3 logs, and thereafter fall only 0.21 logs to plateau-phase 
these two extremes (Munoz et al., 1989; Okoye et al., 2007). 
The mechanisms responsible for these different outcomes 
have not been precisely defined, although differences in adap-
tive immunity, innate immunity, and CD4+, CCR5+ target 
cell availability, susceptibility to infection, productivity (viral 
yield per infected cell), and dynamics have all been implicated 
(Goldstein et al., 2000; Seman et al., 2000; Zhang et al., 2004; 
Alter et al., 2007; Goulder and Watkins, 2008; Lehner et al., 
2008; Mahalanabis et al., 2009).
The HIV/SIV-specific CD8+ T cell response has been 
widely accepted as a major, if not dominant, contributor to 
this heterogeneity of outcomes based on the observations that 
(a) the appearance of these responses is temporally coordinated 
with the postpeak fall in viral replication (Koup et al., 1994), 
(b) vaccines that elicit strong CD8+ T cell responses can lower 
viral replication set points compared with unvaccinated con-
trols (Wilson et al., 2006; Liu et al., 2009), (c) particular class 
1 MHC alleles and their associated CD8+ T cell responses are 
strongly associated with postpeak control of viremia (Goulder 
and Watkins, 2008), (d) viral mutations facilitating escape from 
CD8+ T cell recognition can be associated with either loss of 
virologic control or a fitness cost that handicaps replication of 
escaped virus (Barouch et al., 2002; Goulder and Watkins, 
2008), and (e) treatment of rhesus macaques (RMs) with de-
pleting anti-CD8+ mAbs at the outset of SIV infection, tran-
siently depleting CD8+ lymphocytes from blood and secondary 
lymphoid tissues, typically results in unrestrained viral replica-
tion and rapid disease progression (Matano et al., 1998; Schmitz 
et al., 1999; Kim et al., 2008; Veazey et al., 2008). On the 
other hand, there is considerable circumstantial evidence sug-
gesting that the availability, susceptibility to infection, and cu-
mulative per cell virus production of HIV/SIV target cells may 
also play a major role in determining acute-phase viral dynam-
ics and subsequent viral load set points. In early acute SIV   
infection, the primary target cells are small, resting CD4+, 
CCR5+ TEM and transitional memory T (TTrM) cells in tissues; 
massive infection and destruction of these cells corresponds to 
the initial peak of viral replication and its subsequent decline 
(Picker et al., 2004; Li et al., 2005; Mattapallil et al., 2005). 
With the destruction of resting CD4+ target cells and the onset 
of infection-associated inflammation, the infection shifts to 
predominant replication in activated, proliferating CD4+ TEM 
and TTrM cells (Zhang et al., 2004; Haase, 2005). These obser-
vations suggest that in typical SIV infections, plateau-phase 
viral replication might depend on both the rate of new target 
cell production and the enhanced per cell virus production   
of activated target cells. Consistent with this, it has been well 
documented that both coinfection with other pathogens and 
other modes of immune activation in acute infection, which 
increase the number of activated target cells, are associated 
with increased levels of viral replication and rapid disease pro-
gression (Folks et al., 1997; Zhou et al., 1999; Sequar et al., 
2002; Garber et al., 2004; Cecchinato et al., 2008).
Determination of the interplay between cellular immune 
effector responses and target cell dynamics in the regulation of 
acute-phase HIV/SIV replication will be crucial to understand JEM VOL. 206, July 6, 2009 
ARTICLE
1577
Except for a transient decline immediately after the first 
cM-T807 dose, the absolute counts of CD4+ naive T (TN) 
cells in blood remained steady after CD8+ lymphocyte deple-
tion. In contrast, the absolute counts of total CD4+ memory 
T cells in these RMs progressively increased after day 14, 
peaking, on average, at more than twice their initial levels 
at days 42–70 before declining back toward baseline. This 
memory expansion suggests the development of a CD4+ 
memory T cell “homeostatic” response to CD8+ lymphocyte 
depletion, and in keeping with this, starting at day 3 and 
peaking at day 14 we observed a profound but highly asym-
metric increase in the proliferative fraction of certain CD4+ 
memory T cell subsets (Fig. 2 B). Although both CD4+ TN 
and CD4+, CD28+/CCR7+ TCM T cells showed no or little 
proliferative response to CD8+ lymphocyte depletion, the 
CD4+, CD28+/CCR7 TTrM and the CD4+, CD28, CCR7 
TEM cell subsets manifested moderate and very strong prolif-
erative responses, respectively.
The proliferative asymmetry among CD4+ memory T cell 
subsets in response to CD8+ lymphocyte depletion was 
further explored in two additional SIV-uninfected RMs 
(Fig. 3). In these RMs, CD4+ memory T cell subsets were 
defined by expression patterns of CD28, CCR7, and CCR5, 
allowing precise definition of progressive memory differenti-
ation from CD28+/CCR7+/CCR5 TCM cells to the earliest 
transitional effector memory subset (CD28+/CCR7+/CCR5+ 
TTrM-1), to more mature transitional effector memory cells 
(CD28+/CCR7/CCR5+ TTrM-2), and, finally, to fully differ-
entiated TEM cells (CD28/CCR7/CCR5dim+; Picker et al., 
2006; Grossman and Picker, 2008). As shown in Fig. 3 A, 
the CD4+ memory T cell proliferative response to CD8+ 
lymphocyte depletion followed this differentiation process 
plasma viral loads >4 × 107 copy equivalents/ml (Fig. 1). 
In keeping with these high viral replication rates, all seven of 
the CD8+ lymphocyte–depleted RMs studied in this experi-
ment manifested rapid disease progression, with a median 
time to overt AIDS of 92 d (range = 42–161 d).
CD8+ lymphocyte depletion induces profound proliferation 
and expansion of CD4+, CCR5+ memory T cells in SIV RMs
These plasma viral load patterns indicate that the effect of 
CD8+ lymphocyte depletion on acute-phase SIV replication 
manifests quite early, between PID 10 and 14. Although abro-
gation of developing CD8+ T cell effector responses could 
certainly account for the accelerated viral replication of CD8+ 
lymphocyte–depleted RMs, it is significant that this time 
period also corresponds to the peak of the massive, direct or 
indirect destruction of viral targets (Li et al., 2005; Mattapallil 
et al., 2005), raising the possibility that a limitation in target 
cell availability may also restrict subsequent viral production 
(Haase, 2005). Given the overlap between regulatory factors 
controlling CD4+ and CD8+ population dynamics (Moniuszko 
et al., 2004; Picker et al., 2006; Boyman et al., 2007), CD8+ 
lymphocyte depletion might set in motion a homeostatic reac-
tion that would spur production and/or activation of CD4+, 
CCR5+ memory T cells, and thereby provide additional 
and/or more productive targets for the maintenance of high 
level viral production.
To investigate this latter possibility, we initially assessed the 
effect of CD8+ lymphocyte depletion on CD4+ T cell dynam-
ics in healthy, SIV-uninfected RMs. As shown in Fig. 2 A, 
cM-T807 administration to such RMs completely depleted 
CD8+ T cells from the circulation for 14 d, followed by a 
slow and incomplete recovery over the period of follow up. 
Figure 1.  CD8+ lymphocyte depletion abrogates the postpeak decline in viral replication rates during acute SIVmac239 infection.  
(A and B) Comparison of log-transformed, acute-phase plasma viral load profiles of (A) 23 SIVmac239-infected, untreated normal progressors versus (B) 
7 RMs treated with 10, 5, 5, and 5 mg/kg of the depleting anti-CD8 mAb cM-T807 at days 0, 3, 7, and 10 of SIVmac239 infection, respectively. Normal 
progression was defined as SIV-infected RMs that either manifested disease-free survival for >200 d without antiretroviral treatment or that manifested 
the typical immunological characteristics of normal progression through a minimum of 100 d of untreated infection (Picker et al., 2004; Okoye et al., 
2007). None of the cM-T807–treated RMs expressed class I MHC alleles (Mamu B*08 and B*17) associated with spontaneous SIV control (Goulder and 
Watkins, 2008). The effects of cM-T807 treatment on CD8+ T cell numbers in the blood of these seven RMs are shown in Fig. 5. (C) The means of the log-
transformed plasma viral loads at each time point for each group are shown together. For each RM, the log viral load numbers from days 42–84 were 
averaged to define plateau-phase levels, and the differences between these levels and the viral load peaks were determined so as to define the mean 
“change from peak” for the CD8+ lymphocyte–depleted and control groups. The significance of the difference in these values in the CD8+ lymphocyte–
depleted and control groups was determined by an unpaired Student’s t test, with the p-value shown.1578 CD8 DEPLETION INDUCES SIV TARGET CELL PROLIFERATION | Okoye et al.
30–40 d after the onset of cM-T807 treatment, and the 
absolute CD4+ TEM cell counts peaked still later (day 50), 
indicating that the homeostatic mechanism induced by CD8+ 
lymphocyte depletion has prolonged effects.
It is noteworthy that the frequency of actively proliferat-
ing (Ki-67+) effector site CD4+ T cells (TTrM and/or TEM cells 
in lung airspace and small intestinal lamina propria) was not 
increased at day 7 after CD8+ lymphocyte depletion com-
pared with baseline (unpublished data). These data indicate 
that the stimulation of CD4+ T cells by CD8+ lymphocyte 
depletion primarily affects the cells recirculating among sec-
ondary lymphoid tissues, either via induction or maintenance 
of proliferation in preexisting or developing CD4+ TTrM and 
TEM cells, and/or the simultaneous induction of proliferation 
and  effector  memory  differentiation  among  CD4+  TN  or 
CD4+ TCM cells. However, because induction of proliferation 
among circulating CD4+ TTrM and TEM cells is associated with 
extensive migration of their postproliferative progeny into 
effector sites (Picker et al., 2006; Grossman and Picker, 2008), 
it is highly likely that the expansion of CD4+ TTrM and TEM 
cell populations in response to CD8+ lymphocyte depletion 
does include the extralymphoid effector site compartment.
CD8+ lymphocyte depletion during acute SIV infection  
is associated with the activation and rapid consumption  
of optimal SIV “target” T cells
These data indicate that CD8+ lymphocyte depletion with 
mAb cM-T807 results in the robust activation, proliferation, 
and expansion of CD4+, CCR5+ memory T cells, precisely 
those cells targeted by CCR5-tropic SIV and capable of the 
highest viral production (Picker et al., 2004; Zhang et al., 
2004). As suggested above, it is conceivable that such target 
cell enhancement during the upswing of viral replication in 
acute SIV infection contributes to or even accounts for the 
accelerated viral dynamics and pathogenesis associated with 
CD8+ lymphocyte depletion during acute infection. In keep-
ing with this, we observed that CD8+ lymphocyte depletion 
induces massive proliferation of CD4+ TTrM and, particularly, 
CD4+ TEM cells 7 d after SIV infection, dramatically higher 
than what is observed in control SIV infections at this time 
point (Fig. 4). This effect is quantified for seven cM-T807–
treated versus eight untreated control RMs with acute SIV-
mac239 infection in Fig. 5. The induction of proliferation in the 
CD4+ TTrM and TEM cell populations in cM-T807–treated, 
SIV-infected RMs was similar to that observed in uninfected 
RMs (Fig. 3), but in striking contrast to the uninfected RMs, 
these populations did not increase in size but instead dramati-
cally collapsed, to a much greater extent than control SIV in-
fections (Fig. 5 B). CD4+ TTrM and TEM cells were therefore 
activated and then destroyed in the setting of cM-T807 treat-
ment during acute SIV infection, likely by direct infection. In 
addition, these CD4+ TTrM and TEM cells were not partially 
regenerated by enhanced production, as they typically are in 
control infections. We have previously shown that such new 
CD4+ TTrM and TEM cell production (and AIDS-free sur-
vival) is dependent on inducing and maintaining increased 
precisely, with no response among TCM cells and an increas-
ing response magnitude from TTrM-1 to TTrM-2 to TEM cells. 
Changes in the absolute counts of these subsets in blood were 
in keeping with this pattern of proliferation: CD4+ TCM and 
TTrM-1 cells were, on a fold-change basis, largely stable over 
the course of CD8+ lymphocyte depletion (although show-
ing some random fluctuation); CD4+ TTrM-2 cells were stable 
in one RM, and showed a modest posttreatment increase in 
the other; and CD4+ TEM cell numbers increased dramati-
cally (approximately ninefold) in both RMs. Strikingly, the 
CD4+ TEM cell proliferative response in these RMs lasted for 
Figure 2.  CD8+ lymphocyte depletion of SIV RMs induces CD4+ 
memory T cell proliferation and expansion. (A and B) The effect of 
cM-T807–mediated CD8+ lymphocyte depletion on CD4+ T cell subset 
dynamics was evaluated in seven SIV RMs. Two cohoused untreated SIV 
RMs served as negative controls. (A) The fraction of naive versus memory 
CD4+ T cells in blood was determined by flow cytometric evaluation of 
CD28, CD95, and CCR7 expression patterns (Walker et al., 2004; Picker et al., 
2006), and was used to calculate absolute numbers of these cells, with the 
mean ± SEM shown at each time point relative to cM-T807 treatment (the 
results for the two control RMs are shown individually). Absolute numbers 
of total CD8+ T cells in blood are also shown for the cM-T807–treated RMs. 
In the period from 28 to 70 d after initial treatment, absolute CD4+ memory 
counts were 2.1 ± 0.3–fold higher than at baseline, whereas the absolute 
CD4+ TN cell counts increased by only 1.1 ± 0.02–fold. The two untreated 
RMs showed no net increase in either subset. (B) The proliferative fractions 
of CD4+ TN cells and the CD4+ memory T cell subsets defined by CD28 and 
CCR7 expression were evaluated by determination of the percentage of each 
subset expressing Ki-67. The difference in mean change ± SEM in percent 
Ki-67 from baseline to posttreatment peak was 61.9 ± 3.2, 20.3 ± 2.4, and 
3.9 ± 1.09% for CD28, CCR7 TEM, CD28+, CCR7 TTrM, and CD28+, CCR7+ 
TCM cells, respectively (P < 0.0001, and P = 0.0001 and 0.012, respectively, by 
the paired Student’s t test). The two untreated control RMs showed only 
random fluctuation of percent Ki-67 over the same time period.JEM VOL. 206, July 6, 2009 
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hypothesized that the ability of mAb cM-T807 to abruptly 
deplete CD8+ T cells and NK cells from blood and lymphoid 
tissues would either decrease consumption or increase pro-
duction of IL-15, potentially exposing CD4+ T cells in these 
sites to high levels of this regulatory cytokine. To investigate 
this possibility, we treated two cohorts of CD8+ lymphocyte–
depleted, acutely SIV-infected RMs with either a neutraliz-
ing anti–IL-15 mAb or an isotype-matched control. As shown 
in Fig. 6 A, CD8+ lymphocyte depletion was associated with a 
marked spike in plasma IL-15 levels in the control but not in 
the anti–IL-15–treated RMs. Moreover, the CD4+ TEM cell 
proliferative response to CD8+ lymphocyte depletion was com-
pletely abrogated by the anti–IL-15 mAb, although the smaller 
CD4+ TTrM cell proliferative response was not (Fig. 6 B). 
Most significantly, despite complete inhibition of the CD4+ 
TEM cell proliferative response, the anti–IL-15 treatment did 
not alter the other pathophysiologic characteristics of CD8+ 
lymphocyte–depleted acute infection, including (a) the rapid 
consumption of CD4+ TEM cells, (b) the delayed CD4+ TCM 
cell proliferative response, (c) the lower plateau levels of 
CD4+ TCM cells, (d) the failure to lower postpeak viral repli-
cation, and (e) accelerated disease progression (Fig. 6, B and C). 
The extent of derangement of these parameters was some-
what reduced in both the anti–IL-15– and control-treated 
cohorts compared with the CD8+ lymphocyte–depleted RMs 
presented in Fig. 5 (most likely because of the shorter duration 
proliferation and differentiation of CD4+ TCM cells, the sub-
strate for CD4+ TTrM and TEM cell production (Picker et al., 
2004; Okoye et al., 2007). This response, which characteristi-
cally initiates on approximately PID 17, is significantly de-
layed in the CD8+ lymphocyte–deleted RMs, and CD4+ TCM 
cell populations in these RMs stabilize at significantly lower 
levels than in controls (Fig. 5 B). This compromise of CD4+ 
TCM cell homeostasis and the associated failure of CD4+ TTrM 
and TEM cell production is similar to that observed in spon-
taneous rapid progressors (Picker et al., 2004), and almost 
certainly underlies (or significantly contributes to) the rapid 
clinical progression observed in these RMs.
IL-15 mediates the CD4+ TEM cell proliferative response 
associated with CD8+ lymphocyte depletion, but IL-15 
blockade does not abrogate accelerated viral replication  
and disease progression of CD8+ lymphocyte depletion  
in acute SIV infection
The pattern of selective CD4+ TTrM and TEM cell prolifera-
tion induced by CD8+ lymphocyte depletion is highly remi-
niscent of the effects of in vivo administration of IL-15 in 
RMs (Picker et al., 2006). In addition, IL-15 can promote si-
multaneous proliferation and effector memory differentiation 
among highly purified CD4+ TCM cells (unpublished data), 
consistent with an ability to recruit and expand TTrM and TEM 
cells from recirculating TCM cell precursors. We therefore 
Figure 3.  The effect of CD8+ lymphocyte depletion on CD4+ memory T cell proliferation and expansion is restricted to CCR5-expressing 
cells and increases with progressive effector memory differentiation. (A and B) Two additional SIV RMs were CD8+ lymphocyte–depleted with  
50 mg/kg of mAb cM-T807 at days 0 and 7, and followed for changes in (A) the proliferative fraction and (B) absolute number of circulating CD4+ memory  
T cell subsets defined by CD28, CCR7, and CCR5 expression (TCM → TTrM-1 → TTrM-2 → TEM, from least to most “effector” differentiated).1580 CD8 DEPLETION INDUCES SIV TARGET CELL PROLIFERATION | Okoye et al.
As shown in Fig. 7, exogenous IL-15 induced CD4+ TEM and 
TTrM cell proliferative responses with kinetics similar to CD8+ 
lymphocyte depletion. The magnitude of peak CD4+ TEM 
cell proliferation was slightly reduced compared with that 
observed with CD8+ lymphocyte depletion, but the magni-
tude of the CD4+ TTrM cell proliferative response was equiv-
alent. However, the virologic course of these IL-15–treated 
SIV infections did not recapitulate the CD8+ lymphocyte 
depletion pattern, most notably by the ability of these RMs 
to initially control viral replication rates immediately after the 
PID 10 peak. Indeed, through day 42, the mean plasma viral 
loads of these RMs overlapped those of untreated controls 
(although it is notable that a slight “blip” in viral replication 
was noted at PID 17 in the IL-15–treated group).
IL-15 administration in acute SIV infection has been as-
sociated with accelerated progression (Mueller et al., 2008), 
and strikingly, mean plasma viral loads began to diverge from 
those of the control group at PID 56 and rose to levels associ-
ated with rapid disease progression by PID 84 (Fig. 7 A). 
These data suggest that the accelerated progression of IL-15–
treated RMs is not related to target cell activation and/or 
expansion (which was not apparent immediately before or at 
of CD8+ lymphocyte depletion in this vs. the previous exper-
iment: 17–21 vs. 35 d; Veazey et al., 2008), but the observa-
tion that the anti–IL-15– and control-treated cohorts did not 
show significant differences in these parameters indicates that 
the IL-15-induced CD4+ TEM cell proliferative response is 
not a primary mediator of the accelerated pathogenesis of 
CD8+ lymphocyte depletion.
Administration of recombinant IL-15 during acute SIV 
infection recapitulates the CD4+ TEM and TTrM cell 
proliferation of CD8+ lymphocyte depletion but not  
the immediate postpeak loss of virologic control
Anti–IL-15 did not block the CD4+ TTrM cell proliferative 
response to CD8+ lymphocyte depletion, leaving open the 
possibility that this response, though of smaller magnitude 
than the CD4 TEM cell proliferative response, plays a role in 
supporting the high level, postpeak viral replication charac-
teristic of CD8+ lymphocyte depletion. To address this issue, 
we treated five acutely SIV-infected RMs with 50 µg/kg of 
recombinant IL-15 on PID 0, 3, and 7 (Picker et al., 2006), 
and compared cell dynamic and virologic parameters of these 
RMs with those of untreated, acutely infected controls.   
Figure 4.  CD8+ lymphocyte depletion during acute SIV infection is associated with a marked increase in the proliferating fraction of circu-
lating, CD4+, CCR5+ “SIV targets” during the rising phase of viral replication. (A and B) Representative flow cytometric profiles of CD4+ memory 
subset proliferation at baseline and at 7 d after i.v. inoculation with SIVmac239 in (A) an untreated control RM and (B) an RM treated with 10, 5, 5, and  
5 mg/kg of mAb cM-T807 at days 0, 3, 7, and 10, respectively. The bivariate dot plots in the figure reflect events that were gated on CD3+, CD4+, small 
lymphocytes first, followed by gating on the CD28 versus CD95 profiles to include the overall memory population (Picker et al., 2006). The Ki-67 histo-
grams were gated as shown in the dot plots (pink boxes).JEM VOL. 206, July 6, 2009 
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the developing SIV-specific CD8+ (and perhaps CD4+) T cell 
response to IL-15 might compromise SIV-specific memory 
T cell generation and stability, and thereby account for the 
subsequent loss of virologic control in these IL-15–treated, 
acutely SIV-infected RMs (see Discussion).
DISCUSSION
The ability of HIV and SIV to target the major (CD4+) lin-
eage of memory/effector T cells and to replicate to the highest 
level in activated members of this lineage sets up a dilemma 
for the adaptive immune system: a strong response to infection 
the time of the viral load rise) but rather to a loss of immuno-
logical control. Indeed, it is noteworthy that CD8+ TEM and 
TTrM cells, like their CD4+ counterparts, were highly respon-
sive to IL-15 and manifested a profound burst of proliferation 
at PID 7, followed by an abrupt decline (Fig. 7 C). More-
over, whereas control infections typically manifest and main-
tain an increase in proliferation by CD8+ (as well as CD4+) 
TEM and TTrM cells starting at PID 14–17, almost certainly 
including SIV-specific effectors, these responses were dimin-
ished and/or poorly sustained in IL-15–treated RMs. These 
results suggest that premature and/or excessive exposure of 
Figure 5.  The induction of massive proliferation among CD4+, CCR5+ viral targets accelerates their depletion in acute SIV infection and is 
associated with an inadequate CD4+ TCM cell homeostatic response. (A and B) Comparison of (A) total CD8+ T cell counts and (B) CD4 memory T cell 
subset dynamics in the peripheral blood of seven CD8+ lymphocyte–depleted, SIVmac239-infected RMs (10, 5, 5, and 5 mg/kg of mAb cM-T807 at days  
0, 3, 7, and 10, respectively; black) versus eight control SIVmac239 infections (blue). The viral load profiles of the CD8+ lymphocyte–depleted group are 
shown in Fig. 1. The control group used in this experiment is a subset of the normal progressing SIVmac239 infections shown in Fig. 1. This subgroup had a 
mean ± SEM log-transformed peak (day 10) and plateau phase (days 42–87) viral load of 7.5 ± 0.2 and 5.9 ± 0.3 copies/ml, respectively. The data shown 
reflect the means ± SEM of the designated parameters, presented as either change from preinfection baseline (CD8+ T cell counts and proliferative fraction) 
or the actual measured value (absolute CD4+ memory T cell subset counts). Analysis of the CD4+ TEM cell subset was discontinued at day 28, as this popula-
tion was completely depleted in the majority of CD8+ lymphocyte–depleted RMs by day 35, preventing further analysis. The red arrows indicate analysis of 
the significance of the difference in the designated values by the unpaired Student’s t test, with the p-values shown. Student’s t test analysis of differences 
in plateau-phase CD4+ TCM cell numbers (bottom right) was made after normalization of the data to “change from baseline,” with the p-value shown.1582 CD8 DEPLETION INDUCES SIV TARGET CELL PROLIFERATION | Okoye et al.
Figure 6.  A neutralizing anti–IL-15 mAb specifically blocks the CD4+ TEM cell proliferative response associated with CD8+ lymphocyte depletion 
during acute SIV infection but does not block accelerated viral replication rates or prevent rapid progression in these depleted RMs. 16 RMs that 
were SIVmac239 infected and CD8+ lymphocyte depleted with mAb cM-T807, as described in Fig. 5, were divided into two groups of 8 RMs each, with one 
group additionally receiving the neutralizing anti–IL-15 M111 mAb and the other group receiving an isotype-matched control (both given at 5 mg/kg i.v. on 
days 0, 3, and 7). One RM in the M111-treated group had inadequate CD8+ lymphocyte depletion and was not further considered, leaving a total of seven 
mAb M111-treated and eight control-treated RMs for analysis. (A) The means ± SEM of the change in CD8+ T cell counts from baseline and of the concentra-
tion of plasma IL-15 of the anti–IL-15– (left) and control-treated (right) RMs are shown. The significance of the difference in IL-15 levels in day 5 plasma in 
these two groups was determined by the unpaired Student’s t test, with the p-value shown. (B) The means ± SEM of the change from baseline in percent Ki-67 
within the designated CD4+ memory T cell subsets (top) and of the absolute cell counts of these subsets in blood (bottom) are shown for the anti–IL-15– (red) 
and control-treated (blue) groups. Analysis of the CD4+ TEM cell subset was discontinued at days 21 and 35 for the control- and M111-treated groups, respec-
tively, as this population was completely depleted in the majority of RMs in these groups at these times, preventing further analysis. The significance of the 
differences in Ki-67 between the anti–IL-15– and control-treated groups was determined by the unpaired Student’s t test, with the p-values shown. (C, left) 
The means ± SEM of the log-transformed plasma viral loads of the anti–IL-15– (red) and control-treated (blue) groups are shown, with the significance of JEM VOL. 206, July 6, 2009 
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and precipitates rapid disease progression (Schmitz et al., 1999; 
Veazey et al., 2008). Although it has been long recognized 
that this manipulation eliminates adaptive (and likely innate) 
effector responses to the virus mediated by CD8-expressing 
cells (Schmitz et al., 1999; Choi et al., 2008; Kim et al., 2008; 
Veazey et al., 2008), we further demonstrate that this CD8+ 
lymphocyte depletion instigates a robust proliferative response 
by CD4+ TEM and, to a lesser extent, CD4+ TTrM cell popula-
tions, which both express CCR5 and are known primary tar-
gets of CCR5-tropic SIV (Picker, 2006; Grossman and Picker, 
2008). In uninfected RMs, this CD8+ lymphocyte depletion–
associated proliferative response leads to prolonged expansion 
of CD4+ TEM cells, but in the setting of acute SIV infection, 
such expansion is not observed, and in fact, both circulating 
CD4+ TEM and TTrM cell populations precipitously collapse in 
the early plateau phase of infection. These observations sug-
gest that activation of CD4+ TEM and TTrM cells by CD8+ 
lymphocyte depletion facilitate their infection by SIV, which 
in combination with delayed regeneration from CD4+ TCM 
cell precursors leads to their accelerated loss. As activated 
T cells produce more virus than resting T cells (Zhang et al., 
2004), the profound CD4+ TEM and TTrM cell activation noted 
in our studies might be expected to increase and/or prolong 
high level acute-phase viral replication, perhaps directly pre-
cipitating immune failure as well as facilitating selection of 
viruses capable of efficiently targeting macrophages (which 
are thought to maintain viral replication after memory CD4+ 
T cell depletion; unpublished data; Igarashi et al., 2001).
These potential mechanisms raise the possibility that the 
rapid disease progression associated with CD8+ lymphocyte 
depletion in primary SIV infection may arise, alone or in sig-
nificant part, from enhancing the number of target cells, their 
susceptibility to virus, and the virus yield per infected cell 
rather than loss of immune effector function. In this case, in-
hibition of the CD8+ lymphocyte depletion–associated, CD4+ 
target cell activation might be expected to actually lower post-
peak viral replication rates and ameliorate progression, even in 
the continued absence of CD8+ lymphocytes. This, however, 
was not the case. We were able to demonstrate that the major 
component of CD8+ lymphocyte depletion–associated target 
cell activation, that of CD4+ TEM cells, was IL-15 dependent 
and completely inhibited by a neutralizing anti–IL-15 mAb. 
This abrogation of the CD4+ TEM cell proliferative response 
did not, however, alter the accelerated viral replication and 
pathogenesis typical of CD8+ lymphocyte depletion. CD4+ 
TTrM cells are responsive to IL-2 and IL-7 as well (unpublished 
data; Picker et al., 2006), and the CD8+ lymphocyte deple-
tion–associated proliferation of these cells was not significantly 
might bring to bear potent antiviral effector responses, but 
if it includes a CD4+ T cell response, it will also, inevitably, 
increase both the number of potential target cells and the level 
of virus production per infected target cell, potentially en-
hancing viral replication and accelerating pathogenesis (Douek 
et al., 2002; Staprans et al., 2004; Haase, 2005; Grossman et al., 
2006). This theoretical conundrum has been recognized for 
many years, but the actual, relative contribution of these 
forces to the outcome of acute infection has never been clari-
fied. The ability of adaptive immunity, in particular the CD8+ 
T cell effector response, to modulate HIV/SIV replication 
set points and subsequent pathogenesis is convincingly docu-
mented by evidence of class I MHC allele–associated control 
of infection, either spontaneously or after vaccination (Goulder 
and Watkins, 2008), but the extent to which cellular immune 
responses contribute to the partial (but crucial) plateau-phase 
control of typical infection (those in the individuals without 
clearly protective alleles) is less clear. The massive destruction 
of target cells in acute SIV infection, coincident with the fall 
of plasma viral loads from peak levels, and the subsequent 
switch of viral targeting from resting to activated/proliferating 
targets (Picker et al., 2004; Zhang et al., 2004; Haase, 2005; 
Li et al., 2005; Mattapallil et al., 2005) suggests that target cell 
dynamics may regulate acute-phase viral replication. How-
ever, evidence showing that differences in CD4+ target cell 
numbers, rates of target cell expansion, and/or activation can 
independently determine viral replication set points and the 
pathogenic outcome of acute infection is quite limited, con-
sisting largely of observations that during acute SIV infection, 
simultaneous coinfection with other pathogens or immune 
manipulations increasing CD4+ T cell activation and prolifer-
ation are associated with increased viral replication rates and 
more rapid disease progression (Folks et al., 1997; Zhou et al., 
1999; Sequar et al., 2002; Garber et al., 2004; Staprans et al., 
2004; Cecchinato et al., 2008). Cause and effect have not 
been shown in these studies, but in several instances, a signifi-
cant correlation has been observed between the number of 
activated CD4+ T cells and outcome (Garber et al., 2004; 
Staprans et al., 2004).
In this study, we have used the experimental model of 
CD8+ lymphocyte depletion in acutely SIV-infected RMs to 
directly determine the relative contribution of these two poten-
tially conflicting consequences of immune responsiveness—
target cell augmentation versus antiviral effector responses—to 
viral dynamics and pathogenesis. Previous work has established 
that efficient CD8+ lymphocyte depletion (defined as deple-
tion lasting ≥4 wk) with the CD8-specific cM-T807 mAb 
universally abrogates virologic control in acute SIV infection 
differences between groups assessed by the unpaired Student’s t test. (right) Kaplan-Meier plot of disease-free survival of the two groups, with the statistical 
differences between groups determined by the log-rank test. Note that two animals, one each for the anti–IL-15 and control groups, were lost to follow 
up at day 87 (when disease free), and were censored from this analysis at this time point. Of note, it was retrospectively determined that 1 and 2 of the mAb 
M111–treated and 1 and 4 of the control mAb–treated RMs in this experiment expressed the potentially protective Mamu B*08 and B*17 alleles, respectively, 
but in keeping with the documented ability of CD8+ lymphocyte depletion to abrogate CD8+ T cell–mediated antiviral function (Kim et al., 2008), none of 
these RMs controlled SIV replication and no consistent effect of these alleles on survival was identified.
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similar magnitude and kinetics as CD8+ lymphocyte depletion 
(as well as a CD4+ TEM cell proliferative response), but in 
striking contrast to CD8+ lymphocyte depletion, did not   
inhibited by anti–IL-15. However, administration of recom-
binant IL-15 to CD8+ lymphocyte–intact RMs in acute infec-
tion did induce a CD4+ TTrM cell proliferative response of 
Figure 7.  Recombinant IL-15 induces extensive proliferation among CD4+, CCR5+ viral targets during acute SIV infection but does not  
recapitulate the failure to diminish postpeak viral replication manifested by CD8+ lymphocyte–depleted RMs. (A) The plasma viral load patterns, 
and (B) both CD4+ memory T cell subset dynamics and (C) CD8+ memory T cell subset proliferation in the peripheral blood of five RMs that were 
SIVmac239 infected and treated with 50 µg/kg rhIL-15 on PID 0, 3, and 7 (but are CD8+ lymphocyte intact) in comparison to the same untreated 
SIV-infected controls (A–C) and CD8+ lymphocyte–depleted, SIV-infected RMs (A) shown in Fig. 5. None of the IL-15–treated RMs expressed class I MHC 
alleles (Mamu B*08 and B*17) associated with spontaneous SIV control (Goulder and Watkins, 2008). The data shown reflect the means ± SEM of the 
log-transformed plasma viral loads and the means ± SEM of the designated cellular parameters, presented as either change from preinfection baseline 
(proliferative fraction) or the actual measured value (viral loads, absolute CD4 memory T cell subset counts). Analysis of the significance of the difference 
in the designated values was done by the unpaired Student’s t test (*, P > 0.03 and < 0.08, borderline significance/trends).JEM VOL. 206, July 6, 2009 
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pathogenesis, its effect on viral replication is relatively late 
(after PID 50), long after its stimulation of CD4+ memory 
T  cell  proliferation  (the  current  study;  Mueller  et  al., 
2008). This pattern strongly suggests the initial establish-
ment and then loss of immune control, possibly caused by 
dysregulated development of the SIV-specific T cell and/
or antibody response. Consistent with this, we demon-
strated a significant diminution of CD4+ and CD8+ TEM 
cell proliferation after the viral load peak in IL-15–treated 
versus control RMs in this study (Fig. 7), and Mueller 
et al. (2008) report that IL-15 administration significantly 
changes the character of cellular and humoral immune re-
sponses to SIV in the plateau phase of infection. As IL-15 
potently promotes expansion, differentiation, and effector 
site migration of effector lymphocyte populations (Picker 
et al., 2006), as well as inducing negative regulators of   
itself and other common -chain cytokines (Ramsborg and 
Papoutsakis, 2007), it is quite plausible that premature or 
excessive IL-15 activity would compromise the extent, 
quality, and longevity of a developing pathogen-specific 
immune response. In this regard, it is noteworthy that IL-15 
administration specifically abrogated the protective effects 
of a therapeutic SIV vaccine in SIV-infected, virally sup-
pressed RMs (Hryniewicz et al., 2007). Whether such im-
mune dysregulation is the basis for the accelerated SIV 
disease associated with acute-phase coinfection with other 
agents and other acute-phase immune modulations remains 
to be determined, but given the insensitivity of SIV repli-
cation and disease progression to target cell proliferation/
activation status in this paper, this possibility clearly merits 
further investigation.
The issue of the impact of acute-phase CD4+ memory 
activation on viral replication and pathogenesis has crucial 
implications for HIV/AIDS vaccine development. With few 
exceptions, prophylactic HIV/AIDS vaccines generate spe-
cific CD4+ memory T cell responses that are primed for anam-
nestic expansion and CCR5+ TEM and TTrM cell production 
after pathogenic viral challenge. A central tenet of the HIV/
AIDS T cell vaccine concept is that the T cell effector activ-
ity generated by such responses will outweigh the impact of 
providing more or better viral targets, but there is concern 
for, and some evidence of, such vaccination-induced responses 
making subsequent infection more, rather than less, patho-
genic (Staprans et al., 2004). Although it remains possible that 
the IL-15–mediated homeostatic activation studied in this 
paper differs from the antigen-driven CD4+ T cell expan-
sions that would occur in primary HIV/SIV infections of 
subjects with vaccine-generated HIV/SIV-specific CD4+ 
T cell memory, our data provide some reassurance on this 
issue, suggesting that CD4+ target cell activation and expan-
sion has less effect on the outcome of systemic infection than 
feared. It should be noted that we investigated systemic infec-
tion via i.v. challenge; our data do not speak to the issue 
of whether the number or activation status of CD4+ T cell 
targets in mucosal sites affect the development of HIV/SIV 
infection after mucosal exposure (Li et al., 2009).
result in failure to control postpeak viral loads. At best, IL-15 
treatment induced a slight postpeak blip in viral replication 
(which, interestingly, was also observed in a previous report of 
IL-15 administration in acute SIV infection; Mueller et al., 
2008). Whether this blip was caused by CD4+ target T cell 
activation/expansion is uncertain, but even if it were entirely 
attributable to this mechanism, the effect would clearly be 
quite small. Thus, when the major CD4+ TEM cell prolifera-
tive response is abrogated in the absence of CD8+ cells, or 
when CD4+ TEM and TTrM cell proliferative responses are in-
duced in the presence of CD8+ cells, there is no major change 
in early postpeak viral replication (uncontrolled in the former 
situation, controlled in the latter).
Collectively, these data strongly argue against a major role 
for CD4+ target cell activation and expansion in the initial 
establishment of postpeak viral load set points in acute SIV 
infection, and conversely, strongly imply that functional ac-
tivities of CD8+ lymphocytes play the determining role. The 
adaptive, SIV-specific, CD8+ T cell response is the most ob-
vious candidate for such antiviral activity, and if this is the 
case, it would imply that the delivery of SIV-specific CD8+ 
T cell effectors to sites of viral production at days 10–14 after 
infection is, though not maximal (Reynolds et al., 2005), suf-
ficient to affect viral replication at these sites. However, the 
possibility that this initial control is mediated by innate   
immune function of CD8+ lymphocytes must also be consid-
ered. With respect to this possibility, CD8+ NK cells are 
quite efficiently depleted by cM-T807 treatment (unpub-
lished data) and are, therefore, a potential contributor to 
postpeak  viral  load  control.  The  observation  that  CD16+ 
lymphocyte depletion did not materially alter the virologic 
and clinical course of acute SIV infection argues against a 
major NK cell contribution to this control but does not rule 
it out, because not all RM NK cells express CD16 and the 
depletion reported with the CD16 mAb was not complete 
(Choi et al., 2008). However, NK cells are not the only 
CD8+ cells capable of innate responses: conventional mem-
ory CD8+ T cells can also mediate such innate-like responses 
(Lertmemongkolchai et al., 2001; Kambayashi et al., 2003), 
and the overall memory CD8+ T cell population is obviously 
widely  dispersed,  side-by-side  with  memory  CD4+  viral 
targets, at essentially all potential sites of viral replication 
throughout infection. It is therefore possible that a general-
ized (nonantigen-specific) release of  chemokines or other 
HIV/SIV inhibitory factors (DeVico and Gallo, 2004), in-
duced by innate stimulation, hinders viral spread sufficiently 
to lower postpeak viral loads.
Our  demonstration  that  the  robust  CD4+,  CCR5+ 
memory T cell proliferation induced by CD8+ lympho-
cyte depletion has little effect on subsequent viral dynam-
ics contradicts the prevailing hypothesis that coinfection 
or other immune manipulations leading to CD4+ T cell 
activation and proliferation mediate increased pathogene-
sis by expanding CD4+ target cell populations. In this re-
gard, the effect of IL-15 treatment is illustrative. Although 
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clinical and/or laboratory evidence of opportunistic infection, a wasting 
syndrome  unresponsive  to  therapy,  and/or  non-Hodgkin  lymphoma 
(McClure et al., 1989). RMs that developed disease states that were not 
manageable were euthanized according to the recommendations of the 
AVMA Panel on Euthanasia, American Veterinary Medical Association (2001).
Flow cytometric analysis. Whole blood was obtained and stained for flow 
cytometric analysis as previously described (Walker et al., 2004). Polychro-
matic (8–12 parameter) flow cytometric analysis was performed on an LSR 
II instrument (BD) using Pacific blue, AmCyan, FITC, PE, PE–Texas red, 
PE-Cy7,  PerCP-Cy5.5,  allophycocyanin  (APC),  APC-Cy7,  and  Alexa 
Fluor 700 as the available fluorescent parameters. Instrument set up and data 
acquisition procedures were performed as previously described (Walker   
et al., 2004). List mode multiparameter data files were analyzed using FlowJo 
software (version 6.3.1; Tree Star, Inc.). Criteria for delineating naive and 
memory T cell subsets and for setting + versus  markers for Ki-67 expres-
sion have been previously described in detail (Picker et al., 2006).
mAbs. mAbs L200 (CD4; AmCyan and APC-Cy7), SP34-2 (CD3; Alexa 
Fluor 700), SK1 (CD8; APC-Cy7, PerCP-Cy5.5, and PE-Cy7), CD28.2 
(CD28; PE and PerCP-Cy5.5), B56 (Ki-67; FITC and PE), DX2 (CD95; 
PE, APC, and PE-Cy7), and 3A9 (CCR5; PE and APC) were obtained 
from BD. mAbs 2ST8.5h7 (CD8; PE and PE-Cy7), CD28.2 (PE–Texas 
red), and streptavidin–PE-Cy7 were obtained from Beckman Coulter. mAb 
DK25 (CD8; PE and APC), which is non–cross-reactive with cM-T807, 
was obtained from Dako. FN-18 (CD3) was produced and purified in house 
and conjugated to Pacific blue or Alexa Fluor 700 using a conjugation kit 
from Invitrogen. mAb 150503 (anti-CCR7) was purchased as purified 
immunoglobulin from R&D Systems, conjugated to biotin using a biotinyl-
ation kit (Thermo Fisher Scientific), and visualized with streptavidin–Pacific 
blue (Invitrogen). Production and purification of anti–IL-15 and isotype 
control antibodies was performed using cell lines producing the m111 (anti–
IL-15) and 1B7.11 (anti-TNP–isotype control) antibodies obtained from the 
American Type Culture Collection. Scale-up growth of the hybridomas was 
performed in bioreactors (CL1000; BD). Antibodies were captured from 
growth medium using cation exchange chromatography and further purified 
using recombinant protein A columns. The purified antibodies were dia-
lyzed into PBS and frozen at –80°C before use.
Determination of plasma IL-15 levels. Multiplex kits for measuring cyto-
kines and chemokines on the Luminex platform were obtained from Millipore. 
The kits were used according to the manufacturer’s instructions. Frozen 
plasma samples collected from RMs were thawed rapidly and clarified by 
centrifugation at 10,000 g for 5 min. 25-µl aliquots were used per well in a 
96-well filter plate. Incubations were performed with agitation on a plate 
shaker overnight at 4°C. After the final wash, beads in the 96-well microtiter 
plate were resuspended in 125 µl of Luminex sheath fluid and loaded into the 
Luminex instrument. An acquisition gate was set between 8,000 and 15,000 
for the doublet discriminator, and at least 100 events per region were acquired. 
The IL-15 concentration in the plasma samples were determined by the 
standard curves generated with recombinant rhesus IL-15 using a weighted 
5-parameter logistic method.
Statistical analysis. Statistical analysis was conducted with the programs 
Statview (Abacus Concepts) and SAS version 9.1 (SAS Institute Inc.). Compari-
sons between different groups of animals (treated vs. control) were made using 
unpaired Student’s t tests. The significance of differences between pre- and post-
treatment values was assessed with paired Student’s t tests. The significance of dif-
ferences in disease-free survival was determined with the Kaplan-Meier analysis 
and log-rank testing. In all analyses, a two-sided significance level () of 0.05 was 
used, with correction made for multiple comparisons by the Bonferroni method.
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The major implications of these studies are that the size 
and activation status of CD4+ target cell populations do not 
appear to be primary limiting factors in the replication of 
highly pathogenic, CCR5-tropic SIV in acute infection, 
and that increasing target cell number, infection suscepti-
bility, and/or progeny virus productivity during the rising 
phase of acute-phase SIV replication does not, by itself, sig-
nificantly accelerate the tempo of SIV infection and patho-
genesis. Rather, CD8+ lymphocyte function, innate and/or 
adaptive, appears to play the dominant role in setting this 
tempo, and the increased pathogenicity observed in con-
comitant infection and other settings of generalized im-
mune stimulation is most likely secondary to dysregulation 
of this function. Target cell availability is even less likely to 
be limiting in human HIV infection, as the tempo of viral 
replication and target cell destruction in typical HIV infec-
tion is somewhat slower than that seen in SIV infection of 
RMs (Mellors et al., 1996; Brenchley et al., 2004; Mehandru 
et al., 2004; Mattapallil et al., 2005; Okoye et al., 2007). 
Finally, these studies emphasize the dynamic, reactive nature 
of the in vivo immune system, in particular highlighting 
homeostatic responses to subset perturbations. We describe a 
major homeostatic response to CD8+ lymphocyte depletion 
in primates and define its dependence on IL-15. This is likely 
not the only homeostatic response to CD8+ lymphocyte 
depletion, and it is certain that perturbation of other subsets 
have analogous reactions. This complexity does not under-
mine the value of exploring such experimental perturbations, 
but it does speak to the need to identify such reactive responses 
and define their effects.
MATERIALS AND METHODS
Animals and viruses. A total of 62 purpose-bred male RMs (Macaca mulatta) 
were used in this study, all of Indian genetic background and free of Cerco-
pithecine herpesvirus 1, D type simian retrovirus, simian T-lymphotrophic 
virus type 1, and SIV infection at study initiation. Of this total, 51 were 
infected with SIVmac239 (Kestler et al., 1990) and 11 were used as unin-
fected controls; 32 were CD8+ lymphocyte depleted with mAb cM-T807 
(23 concomitantly infected with SIVmac239 and 9 uninfected; cM-T807 
was provided by the National Institutes of Health [NIH] Nonhuman   
Primate Reagent Resource Program, Boston, MA; Schmitz et al., 1999; 
Veazey et al., 2008); and 5 were treated with rhIL-15 (all SIV infected). 
mAb cM-T807 was administered in multiple doses, typically 10 mg/kg 
(subcutaneous injection) at day 0, followed by three i.v. doses of 5 mg/kg 
at days 3, 7, and 10. An alternative (and functionally equivalent) regimen, 
used in two uninfected RMs (Fig. 3), was 50 mg/kg i.v. at days 0 and 7. 
The anti–IL-15 mAb M111 (American Type Culture Collection; Barzegar 
et al., 1998) and isotype-matched control mAb 1B7.11 (anti-trinitrophenyl 
[TNP]) were administered by i.v. injection at a dose of 5 mg/kg on days 0, 3, 
and 7 (4 h after cM-T807 injection). rhIL-15 was prepared as previously 
described (Villinger et al., 2004) and administered subcutaneously at 50 µg/kg 
at days 0, 3, and 7. SIVmac239 infections were initiated with i.v. injection 
of 5-ng equivalents of SIV p27 (2.7–3 × 104 infectious centers), as previ-
ously described (Picker et al., 2004). Plasma SIV RNA was assessed using a 
real-time RT-PCR assay (Cline et al., 2005) with a threshold sensitivity of 
30 SIV gag RNA copy equivalents per milliliter of plasma. All RMs were 
housed at the Oregon National Primate Research Center according to 
standards of the Animal Care and Use Committee and the NIH Guide for 
the Care and Use of Laboratory Animals (Institute for Laboratory Animal 
Research, 1996). Disease onset (AIDS) was defined by the presence of JEM VOL. 206, July 6, 2009 
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